SCHEMBL26758131

SCHEMBL26758131

COCCn1c(-c2ccc(C(F)(F)F)cc2)nc2ccc([N+](=O)[O-])cc2c1=O

nearest known ligand 0.50

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ABCC1 P33527 2/20 0.50
ABCB1 P08183 1/20 0.50
MEN1 O00255 6/20 0.48
KMT2A Q03164 6/20 0.48
POLB P06746 2/20 0.48
CASR P41180 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
GAA P10253 1/20 0.43
RECQL P46063 1/20 0.43
MAPT P10636 2/20 0.43
HTT P42858 2/20 0.43
NLRP3 Q96P20 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26758117 0.89 POLB (0.60) ABCC1ABCB1MEN1KMT2APOLB
SCHEMBL26758124 0.88 MEN1 (0.52) ABCC1ABCB1MEN1KMT2APOLB
SCHEMBL26758116 0.87 ABCB1 (0.54) ABCC1ABCB1MEN1KMT2APOLB
SCHEMBL24166095 0.84 ABCC1 (0.47) ABCC1POLBCASRSMN1; SMN2MAPT
SCHEMBL26758147 0.82 MEN1 (0.49) ABCC1ABCB1MEN1KMT2APOLB
SCHEMBL26758120 0.81 MEN1 (0.67) MEN1KMT2APOLBSMN1; SMN2GAA
SCHEMBL26758130 0.81 ABCC1 (0.53) ABCC1ABCB1MEN1KMT2APOLB
SCHEMBL30656873 0.81 MEN1 (0.48) ABCC1ABCB1MEN1KMT2APOLB
SCHEMBL26758127 0.81 MEN1 (0.48) ABCC1ABCB1MEN1KMT2APOLB
SCHEMBL26758148 0.80 MEN1 (0.52) MEN1KMT2APOLBSMN1; SMN2GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2023-11-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357165-A1 QUINAZOLINONES DERIVATIVES FOR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE, PREPARATION AND USE THEREOF ATG7, GOT1, LIPC ABCC1 1802/4885ABCB1 2213/4885MEN1 3700/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.